Alka-Seltzer Heartburn ReliefChews Disease Interactions
There are 5 disease interactions with Alka-Seltzer Heartburn ReliefChews (calcium carbonate).
Calcium salts (applies to Alka-Seltzer Heartburn ReliefChews) calcium- phosphate calcifications
Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance
Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. These complexes are eliminated in the feces. Clinical monitoring of serum calcium and phosphate concentrations is necessary.
Calcium salts (applies to Alka-Seltzer Heartburn ReliefChews) cardiac contraction/conduction
Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias
Calcium is involved in cardiac muscle contraction and electrical impulse conduction. Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease. Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias. Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.
Calcium salts (applies to Alka-Seltzer Heartburn ReliefChews) malabsorption
Major Potential Hazard, High plausibility. Applicable conditions: Achlorhydria, Malabsorption Syndrome
Calcium is absorbed from the intestinal tract by active transport and passive diffusion. Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium. Calcium is available in oral and parenteral formulations.
Calcium salts (applies to Alka-Seltzer Heartburn ReliefChews) renal dysfunction
Major Potential Hazard, High plausibility.
Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment. Hyperphosphatemia occurs during renal failure. Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure. Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.
Calcium salts (applies to Alka-Seltzer Heartburn ReliefChews) sarcoidosis
Major Potential Hazard, High plausibility.
Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis. Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma. Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.
Alka-Seltzer Heartburn ReliefChews drug interactions
There are 222 drug interactions with Alka-Seltzer Heartburn ReliefChews (calcium carbonate).
Alka-Seltzer Heartburn ReliefChews alcohol/food interactions
There is 1 alcohol/food interaction with Alka-Seltzer Heartburn ReliefChews (calcium carbonate).
More about Alka-Seltzer Heartburn ReliefChews (calcium carbonate)
- Alka-Seltzer Heartburn ReliefChews consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: antacids
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.